WO2005112922A3 - Benzamide compounds - Google Patents

Benzamide compounds Download PDF

Info

Publication number
WO2005112922A3
WO2005112922A3 PCT/US2005/014131 US2005014131W WO2005112922A3 WO 2005112922 A3 WO2005112922 A3 WO 2005112922A3 US 2005014131 W US2005014131 W US 2005014131W WO 2005112922 A3 WO2005112922 A3 WO 2005112922A3
Authority
WO
WIPO (PCT)
Prior art keywords
mammal
infectivity
symptom
administering
therapy
Prior art date
Application number
PCT/US2005/014131
Other languages
French (fr)
Other versions
WO2005112922A2 (en
WO2005112922A9 (en
Inventor
Laurent Lecanu
Janet Greeson
Vassilios Papadopoulos
Jing Xu
Original Assignee
Samaritan Pharmaceuticals
Univ Georgetown
Laurent Lecanu
Janet Greeson
Vassilios Papadopoulos
Jing Xu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/015791 external-priority patent/WO2004108076A2/en
Priority claimed from PCT/US2004/016126 external-priority patent/WO2005000205A2/en
Application filed by Samaritan Pharmaceuticals, Univ Georgetown, Laurent Lecanu, Janet Greeson, Vassilios Papadopoulos, Jing Xu filed Critical Samaritan Pharmaceuticals
Publication of WO2005112922A2 publication Critical patent/WO2005112922A2/en
Priority to US11/292,797 priority Critical patent/US20060194814A1/en
Publication of WO2005112922A9 publication Critical patent/WO2005112922A9/en
Publication of WO2005112922A3 publication Critical patent/WO2005112922A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen such as a retrovirus toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof that inhibits pathogenic infectivity, including pharmaceutically acceptable salts thereof. The invention also provides a therapeutic method for preventing or treating a neuropathological condition or symptom in a mammal, such as human, comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof, including pharmaceutically acceptable salts thereof.
PCT/US2005/014131 2003-06-02 2005-04-22 Benzamide compounds WO2005112922A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/292,797 US20060194814A1 (en) 2003-06-02 2005-12-02 Benzamide compounds

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US56463604P 2004-04-22 2004-04-22
US60/564,636 2004-04-22
USPCT/US2004/015791 2004-05-20
USPCT/US2004/016126 2004-05-20
PCT/US2004/015791 WO2004108076A2 (en) 2003-06-02 2004-05-20 Anti-hiv benzamide compounds
PCT/US2004/016126 WO2005000205A2 (en) 2003-06-02 2004-05-20 Methods and compositions for modulating serum cortisol levels
US59268804P 2004-07-30 2004-07-30
US60/592,688 2004-07-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/292,797 Continuation US20060194814A1 (en) 2003-06-02 2005-12-02 Benzamide compounds

Publications (3)

Publication Number Publication Date
WO2005112922A2 WO2005112922A2 (en) 2005-12-01
WO2005112922A9 WO2005112922A9 (en) 2006-03-09
WO2005112922A3 true WO2005112922A3 (en) 2007-04-12

Family

ID=35428832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014131 WO2005112922A2 (en) 2003-06-02 2005-04-22 Benzamide compounds

Country Status (1)

Country Link
WO (1) WO2005112922A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514662A (en) * 1991-11-14 1996-05-07 Laboratoires Mayoly Spindler (S.A.R.L.) Use of amphotericin B derivatives as protease inhibitors
WO2000015657A1 (en) * 1998-09-12 2000-03-23 Astrazeneca Ab Piperizine-4-phenyl derivatives as inhibitors of the interaction between mdm2 and 53
WO2000076970A2 (en) * 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
WO2002018623A2 (en) * 2000-09-01 2002-03-07 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Methods and reagents for protease inhibition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514662A (en) * 1991-11-14 1996-05-07 Laboratoires Mayoly Spindler (S.A.R.L.) Use of amphotericin B derivatives as protease inhibitors
WO2000015657A1 (en) * 1998-09-12 2000-03-23 Astrazeneca Ab Piperizine-4-phenyl derivatives as inhibitors of the interaction between mdm2 and 53
WO2000076970A2 (en) * 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
WO2002018623A2 (en) * 2000-09-01 2002-03-07 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Methods and reagents for protease inhibition

Also Published As

Publication number Publication date
WO2005112922A2 (en) 2005-12-01
WO2005112922A9 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
CA2883751C (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
WO2005108378A3 (en) Use of (4-alkylpiperazinyl) (phenyl) methanones in the treatment of alzheimer’s disease
EA200800006A1 (en) TRIAZOLOPIRIDIN AS AN INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I
WO2006042150A8 (en) Diaminoalkane aspartic protease inhibitors
NO20065847L (en) Diphenylimidazopyrimidines and imidazolamines as inhibitors of B-secretase
NO20074999L (en) Method and preparation for the treatment of peripheral vascular diseases
FI3157527T3 (en) Ezh2 inhibitors for treating lymphoma
NO20074697L (en) Non-aromatic nitrogen-containing heterocyclic 1-carboxylate ester pyridyl derivative
EA200800147A1 (en) METHOD OF OBTAINING OLMESARTAN MEDOKSOMIL
EA201790406A1 (en) KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE
DOP2005000039A (en) HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) - PIPERIDIN-1-IL] - (4-BOMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
EA201490163A1 (en) KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE
NZ592615A (en) Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
DK1546127T3 (en) New pyrimidinamide derivatives and their use
BR0316458A (en) Compound, pharmaceutical composition, method of treating or preventing disease, method for enhancing cognition in a healthy patient, and use of a compound
SE0400184D0 (en) New therapeutic use
TW200732304A (en) Piperidine derivatives
WO2007034329A3 (en) Compounds and methods for treatment of amyloid-beta-peptide related disorders
NZ592613A (en) Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
ATE499933T1 (en) USE OF BETAIN TO TREAT INTERMITTENS CLAUDICATIO
WO2004108666A3 (en) Neuroprotective benzoate and benzamide compounds
WO2005089453A3 (en) Benzamide and benzoate anti-hiv compounds
WO2005112922A3 (en) Benzamide compounds
WO2004108076A3 (en) Anti-hiv benzamide compounds
TW200700075A (en) Roflumilast and integrin inhibitor combination and method of treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 11292797

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/15-15/15, DRAWINGS, REPLACED BY NEW PAGES 1/21-21/21; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 11292797

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase